SciELO - Scientific Electronic Library Online

 
vol.142 issue4The role of the psychiatrist in obtaining informed consent from patients with somatic and mental comorbidity: Report of one caseFirst successful bridge to cardiac transplantation in Chile using the Heart Mate II device. Report of one case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

TORRES C, Demetrio  and  CHANDIA, Mauricio. Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case. Rev. méd. Chile [online]. 2014, vol.142, n.4, pp.516-520. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872014000400015.

We report a 58 year-old-man without comorbid conditions, with a history of two months of weight loss, malaise and headache. His initial laboratory analysis showed leukocytosis of 16,100/mL with 65% eosinophils and an absolute eosinophil count of 10,465/mL. Both bone marrow biopsy and aspirate showed infiltration by mature appearing eosinophils. Treatment was started with hydroxyurea, associated with prednisone without satisfactory decrease in the eosinophil count. Polymerase chain reaction showed the presence of the gene fusion product FIP1L1/PDGFRA. Imatinib therapy was initiated, resulting in a rapid and progressive reduction in the absolute eosinophil count, with normalization at the second week of treatment. The incidence of the myeloproliferative variant causing hypereosinophilic syndrome is rare. However, the dramatic response to imatinib emphasizes the need to study the presence of the fusion product FIP1L1/PDGFRA in all patients with eosinophilia of unknown etiology.

Keywords : Hypereosinophilic syndrome; imatinib; Leukemoid reaction.

        · text in Spanish     · Spanish ( pdf )